QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
OTCMKTS:NWBO

Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis

$0.54
-0.01 (-1.82%)
(As of 02/28/2024 ET)
Today's Range
$0.54
$0.56
50-Day Range
$0.54
$0.82
52-Week Range
$0.40
$1.09
Volume
2.01 million shs
Average Volume
1.83 million shs
Market Capitalization
$642.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NWBO stock logo

About Northwest Biotherapeutics Stock (OTCMKTS:NWBO)

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

NWBO Stock Price History

NWBO Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Northwest Biotherapeutics Inc NWBO
Northwest Bio: Another Small Filing Delay
Northwest Missouri State University
Northwest Hospital
HCA Houston Healthcare Northwest
NWBO - Northwest Biotherapeutics, Inc.
Northwest Medical Center-Tucson
See More Headlines
Receive NWBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2015
Today
2/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:NWBO
Previous Symbol
NASDAQ:NWBO
Employees
22
Year Founded
N/A

Profitability

Net Income
$-105,030,000.00
Net Margins
-3,453.84%
Pretax Margin
-3,453.84%

Debt

Sales & Book Value

Annual Sales
$1.68 million
Book Value
($0.12) per share

Miscellaneous

Outstanding Shares
1,188,730,000
Free Float
1,023,498,000
Market Cap
$642.03 million
Optionable
Not Optionable
Beta
-0.67
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Ms. Linda F. Powers J.D. (Age 68)
    Chairperson, CEO, President, CFO & Chief Accounting Officer
    Comp: $1.1M
  • Dr. Alton L. Boynton Ph.D. (Age 79)
    Founder, Chief Scientific Officer, Secretary & Director
    Comp: $450k
  • Dr. Marnix L. Bosch M.B.A. (Age 65)
    Ph.D., Chief Technical Officer
    Comp: $597.5k
  • Mr. Leslie J. Goldman (Age 79)
    Senior VP & General Counsel
    Comp: $825k
  • Ms. Jean M. Davis (Age 52)
    Chief Information Officer
    Comp: $258.78k
  • Mr. David Innes
    Vice President of Investor Relations
  • Mr. Pankaj R. Shah C.A.
    CPA, Financial Controller














NWBO Stock Analysis - Frequently Asked Questions

How have NWBO shares performed in 2024?

Northwest Biotherapeutics' stock was trading at $0.7010 on January 1st, 2024. Since then, NWBO stock has decreased by 23.0% and is now trading at $0.5401.
View the best growth stocks for 2024 here
.

When is Northwest Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our NWBO earnings forecast
.

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) posted its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.22. The biotechnology company had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.20 million.

What other stocks do shareholders of Northwest Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), (ZLTQ) (ZLTQ), Avid Bioservices (CDMO), Idera Pharmaceuticals (IDRA), Amarin (AMRN), Inovio Pharmaceuticals (INO) and MEI Pharma (MEIP).

How do I buy shares of Northwest Biotherapeutics?

Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NWBO) was last updated on 2/28/2024 by MarketBeat.com Staff